Delgocitinib

Delgocitinib is an inhibitor of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2, IC50s = 2.8, 2.6, 13, and 58 nM, respectively). It is selective for JAK1, JAK2, JAK3, and TYK2 over lymphocyte cell-specific tyrosine kinase (LCK, IC50 = 5,800 nM). Delgocitinib inhibits IL-31-induced increases in STAT3 phosphorylation levels in A549 cells (IC50 = 25 nM). It reduces IL-31-induced scratching in mice in a dose-dependent manner. Formulations containing delgocitinib have been used in the treatment of atopic dermatitis.Formal Name: (3S,4R)-3-methyl-beta-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octane-1-propanenitrile. CAS Number: 1263774-59-9. Synonyms: JTE-052. Molecular Formula: C16H18N6O. Formula Weight: 310.4. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 30 mg/ml, DMSO: 30 mg/ml. lambdamax: 214, 285 nm. SMILES: O=C(N(C1)[C@]2([C@H]1C)CN(C3=C(C=CN4)C4=NC=N3)CC2)CC#N. InChi Code: InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1. InChi Key: LOWWYYZBZNSPDT-ZBEGNZNMSA-N.